Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 7/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 3/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR1F | P30939 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069575 | 0.81 | HTR1D (0.47) | HRH3CHRM4SMN1; SMN2HTR1DHTR1B | |
| SCHEMBL20147424 | 0.77 | HRH3 (0.52) | HRH3 | |
| SCHEMBL5268383 | 0.75 | GPR119 (0.47) | GPR119HRH3GLS | |
| SCHEMBL2772792 | 0.74 | GPR119 (0.46) | GPR119HRH3GLS | |
| SCHEMBL21733092 | 0.74 | RET (0.38) | OXTRAVPR1AGPR119RETGLS | |
| SCHEMBL24308695 | 0.73 | HRH3 (0.53) | HRH3RET | |
| SCHEMBL20412703 | 0.73 | HRH1 (0.47) | HRH3SMN1; SMN2 | |
| SCHEMBL22857007 | 0.72 | PDGFRB (0.36) | OXTRAVPR1AGPR119HRH3CHRM4 | |
| SCHEMBL25071302 | 0.71 | SMN1; SMN2 (0.53) | HRH3SMN1; SMN2 | |
| SCHEMBL30986470 | 0.71 | HRH3 (0.42) | HRH3CHRM4SMN1; SMN2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OXTR 3773/4885AVPR1A 1841/4885GPR119 1905/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OXTR 3773/4885AVPR1A 1841/4885GPR119 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.